Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.
Authors
Illidge, Timothy MBayne, Mike
Brown, Nicholas S
Chilton, Samantha
Cragg, Mark S
Glennie, Martin J
Du, Yong
Lewington, Valerie
Smart, James
Thom, James
Zivanovic, Maureen
Johnson, Peter W
Affiliation
School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. tmi@manchester.ac.ukIssue Date
2009-02-12
Metadata
Show full item recordAbstract
The effect of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown. We evaluated a novel protocol using 4 weekly infusions of 375 mg/m(2) rituximab followed by 2 fractions of (131)I-rituximab, preceded by a 100-mg/m(2) predose of rituximab, in relapsed indolent B-cell lymphoma. Induction therapy with rituximab significantly increased the effective half-life of (131)I-rituximab (P = .003) and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radioimmunoconjugate (P = .009). Patients with large tumor burdens experienced significant increases in the effective half-life of (131)I-rituximab between delivery of the first and second fractions (P = .007). Induction therapy with multiple doses of rituximab did not appear to compromise the clinical efficacy or increase toxicity of subsequent (131)I-rituximab radioimmunotherapy. The overall response rate was 94%, with complete response rate 50%. The median time to progression was 20 months, significantly longer than for the last qualifying chemotherapy (P = .001). Fractionation of (131)I-rituximab allowed cumulative whole-body doses of more than 120 cGy, approximately 60% greater than those previously achieved with a single administration of a murine radioimmunconjugate, to be delivered without significant hematologic toxicity.Citation
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. 2009, 113 (7):1412-21 BloodJournal
BloodDOI
10.1182/blood-2008-08-175653PubMed ID
19074729Type
ArticleLanguage
enISSN
1528-0020ae974a485f413a2113503eed53cd6c53
10.1182/blood-2008-08-175653
Scopus Count
Collections
Related articles
- Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
- Authors: Leahy MF, Seymour JF, Hicks RJ, Turner JH
- Issue date: 2006 Sep 20
- Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
- Authors: Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR
- Issue date: 2001 Jul-Aug
- Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.
- Authors: Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF
- Issue date: 2008 Sep
- Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
- Authors: Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL
- Issue date: 2005 Oct
- Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
- Authors: Wagner JY, Schwarz K, Schreiber S, Schmidt B, Wester HJ, Schwaiger M, Peschel C, von Schilling C, Scheidhauer K, Keller U
- Issue date: 2013 Jun